Abliva: Potentially faster to market
Redeye maintains its fair value of Abliva at SEK 1.4 per share. Optimism around its main asset, KL1333, has increased, but there are still many unknowns concerning clinical outcomes and financing.
Sign up for free to continue
Already a member?
Disclosures and disclaimers
Premium Plan required to unlock